Fairvalue-Calculator Fairvalue-Calculator
EN DE

Thor Medical ASA (TRMED) Fair Value & Analysis

Healthcare · NO · Market cap 1.7B NOK

Pricekr 4.24
Fair Valuekr 5.70
Upside+34.4%
Quality95/100
Evidence: Low Range kr 4.28 – kr 7.13

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Thor Medical ASA (TRMED) currently trades at kr 4.24, while our model-based Fair Value estimate is kr 5.70 — implying the stock looks roughly 34.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Thor Medical ASA (TRMED) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 5.70 versus a price of kr 4.24 — about +34% (undervalued). Model-based estimate, not financial advice.
What is the fair value of TRMED?
Our 21-model fair value for Thor Medical ASA is kr 5.70 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 4.24.
What is the quality score of TRMED?
Thor Medical ASA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.